Hologic, Inc. (NASDAQ:HOLX) Holdings Reduced by Cerity Partners LLC

Cerity Partners LLC lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 51,687 shares of the medical equipment provider’s stock after selling 4,877 shares during the quarter. Cerity Partners LLC’s holdings in Hologic were worth $3,193,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in Hologic in the 4th quarter valued at approximately $133,414,000. Champlain Investment Partners LLC bought a new position in shares of Hologic in the fourth quarter worth $79,291,000. Redwood Wealth Management Group LLC acquired a new position in shares of Hologic during the first quarter valued at $3,534,000. Northern Trust Corp raised its stake in shares of Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock valued at $226,898,000 after purchasing an additional 668,086 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock worth $293,434,000 after purchasing an additional 572,187 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Mizuho boosted their target price on Hologic from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday. Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. Finally, Evercore ISI boosted their price objective on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 8th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has an average rating of “Hold” and an average target price of $77.33.

Hologic Trading Down 0.0%

Shares of HOLX opened at $63.99 on Friday. The business’s 50-day moving average price is $62.46 and its 200 day moving average price is $63.25. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $14.26 billion, a P/E ratio of 27.00, a P/E/G ratio of 2.35 and a beta of 0.55. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the firm posted $1.03 earnings per share. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares of the company’s stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.